Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. IBM
5. META
6. SPY
7. ACN
8. NVDA
9. PRIM
10. PFE

Go back to Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
ALKERMES (NASDAQ: ALKS) Delayed: 47.90 +1.88 (4.09%)
Previous Close $46.02    52 Week High $80.71 
Open $46.00    52 Week Low $27.14 
Day High $48.07    P/E 368.46 
Day Low $45.47    EPS $0.13 
Volume 795,241